Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Mendus Q2´24: The CADENCE trial has started

By Antti SiltanenAnalyst
Mendus

Mendus released their Q2 report today 23/8 and in this interview, you can listen to CEO Erik Manting summarize the second quarter. What has happened during Q2, main milestones in CADENCE and the new communicated trial with Ilixadencel.

00:00 Start
00:14 What has happened during Q2
04:58 The CADENCE trial
08:04 Main milestones in CADENCE
09:36 Immune activation in AML patients - What have you learned?
12:19 New trial with Ilixadencel
15:16 Timeline for the trial
15:54 Building readiness in AML

Stay up to date
Company management interviews

Recent videos

A sit-down with CEO Remco Westermann
12.12.2025 klo 10.09 Verve Group
Aiforia as an Investment | Life Science Night Dec 9, 2025
11.12.2025 klo 12.00 Aiforia Technologies
Endomines as an Investment | Investor Day Nov. 24, 2025
10.12.2025 klo 13.30 Endomines Finland
Clas Ohlson, Audiocast, Q2'25
10.12.2025 klo 10.00 Clas Ohlson
Herantis Pharma as an Investment | Life Science Night Dec 9, 2025
09.12.2025 klo 23.11 Herantis Pharma
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.